BMS and Gilead establish landmark HIV venture

home   >   blogdigger

Bristol-Myers Squibb and Gilead Sciences have established a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb's Sustiva and Gilead's Truvada for the treatment of HIV in the US.

- link to BMS and Gilead establish landmark HIV venture -
Last update: 05/26/2005

Recommended Reading

    Barrio, Macedo de la Concha y Peyrot: Impugnables.(actos polticos comprometedores de candidatos ministeriales; Mxico)(TT: Barrio, Macedo de la Concha ... o)(Artculo Breve) : An article from: Siempre!
    IM formulations widen atypical antipsychotic uses: intramuscular ziprasidone, others.(Psychopharmacology) : An article from: Clinical Psychiatry News
    Advair Diskus bests Combivent for COPD.(Pulmonary Medicine)(chronic obstructive pulmonary disease ) : An article from: Family Practice News
    Panel Revisits Safety Data on COX-2 Drug Labels.(Brief Article) : An article from: Family Practice News
    Zyprexa - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
    Barrio, Macedo de la Concha y Peyrot: Impugnables.(actos polticos comprometedores de candidatos ministeriales; Mxico)(TT: Barrio, Macedo de la Concha ... o)(Artculo Breve) : An article from: Siempre!
    Natalizumab maintains remission in Crohn's; drug blocks immune cell movement.(News) : An article from: Family Practice News
    Drug shortages increase in number, severity. ('Serious Business'). : An article from: Skin & Allergy News